Grenoble, July 8th, 2021 – LXRepair, a biotechnology start-up specializing in personalized medicine testing, today announces the granting of €750,000 in funding under the BPI France DeepTech program. This program supports advanced and highly differentiating biotechnology projects with significant commercial potential.
This is the case of LXRepair: predicting serious late side effects is the “Holy Grail” of radiotherapists. Caused by DNA repair defects, they affect 5 to 30% of patients and cost around 600 million euros per year in Europe and the United States for breast and prostate cancers alone.
Contact:
Sylvie Sauvaigo: +33. 6.21.21.77.95. sylvie.sauvaigo@lxrepair.com
Stéphane Altaba : +33.6.72.87.20.03. stephane.altaba@lxrepair.com
Media Relations: Jean-Baptiste Mounier: +33.7.67.47.42.91. jean-baptiste.mounier@lxrepair.com
Leave a Reply
Want to join the discussion?Feel free to contribute!